May Sabry is a senior research fellow at the Centre for Cell, Gene and Tissue Therapeutics at University College London. She obtained her MSc in Molecular Medicine, and PhD in Cancer Immunology from University College London as a Qalaa Holdings Scholar, studying natural killer responses to tumor-priming, where she co-invented a patented mechanism for NK cell activation for use in cancer immunotherapy. She completed postdoctoral training in Cancer Genomics at Harvard Medical School and Hubrecht Institute, where she worked on CRISPR-based gene-editing of tumor-suppressor genes. Currently, she is involved in research that aims to define NK cell interactions with tumor targets, for the development of NK cell-based medicine in cancer.
RESEARCH ARTICLE :
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures.
News 
Market Data 
Discover 
AI
